IWR-1-endo is a Wnt signaling protein, which are small secreted proteins that are active in embryonic development, tissue homeostasis, and tumorigenesis. Wnt proteins bind to receptors on the cell surface, initiating a signaling cascade that leads to β-catenin activation of gene transcription. IWR-1-endo is a potent inhibitor of the Wnt response, blocking a cell-based Wnt/β-catenin pathway reporter response with an IC50 value of 180 nM. It inhibits, at 10 μM, Wnt-induced accumulation of β-catenin, leading to proteasomal degradation of this protein through a destruction complex which consists of Apc, Axin2, Ck1, and Gsk3β. IWR-1-endo stabilizes the destruction complex, increasing the level of Axin2 protein without changing the levels of Apc or Gsk3β. The IWR compound does not change the de novo synthesis of Axin2, alter the affinity of Axin2 for β-catenin, or inhibit the proteasome. It has a half-life of 60 minutes in murine whole blood and 20 minutes in intact murine hepatocytes. In in vivo tests, IWR-1-endo inhibits zebrafish tail fin regeneration with a minimum inhibitory concentration of 0.5 μM. The IWR-1-exo diastereomer exhibits much less activity against the Wnt/β-catenin pathway and has been used as a control. IWR-1-endo is an inhibitor of Tankyrase-1 and Tankyrase-2.
1. Polakis, P., et al., 2000. Wnt signaling and cancer. Genes & development. 14(15): 1837-51. PMID: 10921899
2. Reya, Tannishtha., et al., 2005. Wnt signalling in stem cells and cancer. Nature. 434(7035): 843-50. PMID: 15829953
3. Clevers, Hans., et al., 2006. Wnt/beta-catenin signaling in development and disease. Cell. 127(3): 469-80. PMID: 17081971
4. Chen, Baozhi., et al., 2009. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nature chemical biology. 5(2): 100-7. PMID: 19125156
5. Lu, Jianming., et al., 2009. Structure-activity relationship studies of small-molecule inhibitors of Wnt response. Bioorganic & medicinal chemistry letters. 19(14): 3825-7. PMID: 19410457
See how others have used IWR-1-endo (CAS 1127442-82-3). Click on the entry to view the PubMed entry .
PMID: # 30899376 Li, SJ.|Kao, YH.|Chung, CC.|Cheng, WL.|Chen, YJ.| et al. 2019. Am J Transl Res. 11: 744-754.
PMID: # 29055830 Fujita, S. et al. 2018. Bone. 106: 156-166.
PMID: # 27477297 Lu, C. et al. 2016. Toxicology. 365: 35-47.
PMID: # 26899563 Zhu, J. et al. 2016. Scientific reports. 6: 21549.
PMID: # 26048374 Mathur, R. et al. 2015. J Hematol Oncol. 8: 63.
PMID: # 26003048 Lee, S. et al. 2015. Molecular oncology. 9: 1599-611.
PMID: # 25963533 Xu, Z. et al. 2015. Journal of molecular neuroscience : MN. 56: 397-408.
PMID: # 21968810 Yasuhara, R. et al. 2011. Laboratory investigation; a journal of technical methods and pathology. 91: 1739-52.
PMID: # 32584132 Physiol Res.
PMID: # 32444641 Nat Commun. 11: 2591.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.